- Conditions
- Coronary Artery Disease
- Interventions
- SYNERGY 48 mm
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Saint Paul, Minnesota • New York, New York + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 913–936
of 1,745
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Coronary Artery Disease
- Interventions
- TAXUS Liberté Paclitaxel-Eluting Coronary Stent, prasugrel, placebo, aspirin
- Device · Drug
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 82
- States / cities
- Mesa, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 72 more
- Conditions
- Pain
- Interventions
- Marketed paracetamol, Experimental paracetamol formulation
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Breast Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Abraxane, Alimta
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Bipolar I
- Interventions
- Aripiprazole
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 748 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 62 more
- Conditions
- Coronary Artery Disease, Atherosclerosis, Coronary, Myocardial Ischemia, Ischemic Heart Disease, Acute Coronary Syndrome, Angina Pectoris
- Interventions
- Orsiro DES
- Device
- Lead sponsor
- Biotronik, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 556 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 33
- States / cities
- Fairhope, Alabama • Concord, California • Orange, California + 26 more
- Conditions
- Schizophrenia, Cognition, Psychosis
- Interventions
- Curcumin, Placebo
- Drug
- Lead sponsor
- VA Greater Los Angeles Healthcare System
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Brain Tumor, Medulloblastoma, Brain Metastases
- Interventions
- WP1066
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Schizophrenia
- Interventions
- aripiprazole IM depot, aripiprazole tablets
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 7
- States / cities
- Cerritos, California • Garden Grove, California • Glendale, California + 4 more
- Conditions
- Infection, Post-operative Care
- Interventions
- Novel Microbicidal Liquid Polymer
- Device
- Lead sponsor
- Prevent-Plus LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Chronic Myeloid Leukemia (CML), Pancreatic Ca, Colon/Rectal Ca, Multiple Myeloma, Carcinoma, Non-Small -Cell Lung
- Interventions
- Bortezomib, NK cells
- Drug · Biological
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- COVID-19 Pneumonia
- Interventions
- PF-06650833, Matching Placebo
- Drug
- Lead sponsor
- Giovanni Franchin, M.D, Ph.D
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Prostate Neoplasms
- Interventions
- Stage 1 Group 1: abiraterone acetate, Stage 1 Group 2: abiraterone acetate, Stage 2: abiraterone acetate, Stage 3: abiraterone acetate, Stage 3: glucocorticoid, Stage 4: abiraterone acetate, Stage 4: glucocorticoid
- Drug
- Lead sponsor
- Cougar Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Neurogenic Bladder, Spinal Cord Injuries
- Interventions
- Gentamicin Sulfate, Placebo instillation (saline alone), No instillation
- Drug · Other
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Healthy
- Interventions
- Tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF), Tapentadol Prolonged-Release Formulation 2 (PR2)
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Allergic Rhinitis, Chronic Urticaria
- Interventions
- Levocetirizine 1.25 mg, Placebo
- Drug · Other
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 6 Months to 11 Months
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Hot Springs, Arkansas • Jonesboro, Arkansas + 23 more
- Conditions
- Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
- Interventions
- AZD4635, Durvalumab, Abiraterone Acetate, Enzalutamide, Oleclumab, Docetaxel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 17
- States / cities
- Fayetteville, Arkansas • Fresno, California • Denver, Colorado + 14 more
- Conditions
- Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
- Interventions
- VP-102, Vehicle
- Combination Product
- Lead sponsor
- Verrica Pharmaceuticals Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 17
- States / cities
- Miami, Florida • Saint Augustine, Florida • Meridian, Idaho + 13 more
- Conditions
- HIV Infections
- Interventions
- Cabotegravir IR Formulation (reference), Cabotegravir DT Formulation (test 1), Cabotegravir DT Formulation (test 2)
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Opioid-Related Disorders
- Interventions
- Buprenorphine formulation: liquid vs. tablet
- Drug
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 1999
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Glaucoma, Glaucoma Eye, Glaucoma, Open-Angle
- Interventions
- Lumega-Z, Dorzolamide Hcl 2% Oph Soln, Placebo
- Dietary Supplement · Drug · Other
- Lead sponsor
- University of the Incarnate Word
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood
- Interventions
- Ixazomib, Vincristine, Dexamethasone, Asparaginase, Doxorubicin, Methotrexate (IT), Triple IT (Methotrexate, Hydrocortisone, Cytarabine), Leucovorin
- Drug
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 14 more
- Conditions
- Menopause
- Interventions
- Estradiol, Progesterone, Placebo
- Drug
- Lead sponsor
- TherapeuticsMD
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 1,845 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 119
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 99 more
- Conditions
- COVID-19
- Interventions
- Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated, Not vaccinated with 2024-2025 formulated COVID-19 vaccine
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York